Literature DB >> 19127534

Racial differences in myasthenia gravis in Alabama.

Shin J Oh1, Marla B Morgan, Liang Lu, Yuki Hatanaka, Shoji Hemmi, Angela Young, Gwendolyn C Claussen.   

Abstract

Demographic, clinical, and laboratory features were compared in 235 white and African-American (AA) patients with myasthenia gravis (MG) at the University of Alabama at Birmingham Neuromuscular Disease Clinic from May 2003 to January 2008. Seventy nine percent of patients were white. Acetylcholine receptor antibody was positive in 71% of white patients and in 59% of AA. In patients with seronegative generalized MG, the rate of positive muscle-specific tyrosine kinase antibody (MuSK-Ab) was significantly higher in AA than it was in whites (50% in AA vs. 17% in whites). Ocular MG was seronegative in 75% of AA patients. In AA, MG occurred earlier and more frequently in females, whereas, in whites, disease onset was later and more common in males. Another significant difference was a higher percentage of abnormality on repetitive nerve stimulation in AA. There was also a tendency for more severe forms of MG in AA. There are racial differences in MG between whites and AA in Alabama. These racial differences highlight the need to study biological factors in the pathogenesis of MG and to assess different approaches in diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127534      PMCID: PMC2814330          DOI: 10.1002/mus.21191

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  18 in total

1.  Diagnostic sensitivity of the laboratory tests in myasthenia gravis.

Authors:  S J Oh; D E Kim; R Kuruoglu; R J Bradley; D Dwyer
Journal:  Muscle Nerve       Date:  1992-06       Impact factor: 3.217

2.  The epidemiology of myasthenia gravis in central and western Virginia.

Authors:  L H Phillips; J C Torner; M S Anderson; G M Cox
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

3.  The relationship of age to outcome in myasthenia gravis.

Authors:  D H Donaldson; M Ansher; S Horan; R B Rutherford; S P Ringel
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

4.  Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis.

Authors:  P I Andrews; J M Massey; J F Howard; D B Sanders
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

5.  The natural course of myasthenia gravis and effect of therapeutic measures.

Authors:  D Grob; N G Brunner; T Namba
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

6.  Electrophysiological and clinical correlation in myasthenia gravis.

Authors:  S J Oh; N Eslami; T Nishihira; P K Sarala; T Kuba; R S Elmore; I N Sunwoo; Y I Ro
Journal:  Ann Neurol       Date:  1982-10       Impact factor: 10.422

Review 7.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

8.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

9.  Myasthenia gravis in South Africans: racial differences in clinical manifestations.

Authors:  J M Heckmann; E P Owen; F Little
Journal:  Neuromuscul Disord       Date:  2007-08-27       Impact factor: 4.296

10.  Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians.

Authors:  H C Chiu; A Vincent; J Newsom-Davis; K H Hsieh; T Hung
Journal:  Neurology       Date:  1987-12       Impact factor: 9.910

View more
  8 in total

1.  Circulating microRNA plasma profile in MuSK+ myasthenia gravis.

Authors:  Liis Sabre; Jeffrey T Guptill; Melissa Russo; Vern C Juel; Janice M Massey; James F Howard; Lisa D Hobson-Webb; Anna Rostedt Punga
Journal:  J Neuroimmunol       Date:  2018-10-06       Impact factor: 3.478

2.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

3.  Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society.

Authors:  Hakan Cetin; Gerhard Fülöp; Heidemarie Zach; Eduard Auff; Fritz Zimprich
Journal:  Wien Klin Wochenschr       Date:  2012-11-06       Impact factor: 1.704

4.  Clinical delineation of myasthenia gravis in the Kingdom of Bahrain.

Authors:  Mohamed F Binfalah; Hussein H Alhafnawi; Ahmed A Jaradat; Eslam Shosha; Ali J Alhilly; Firas K Al Nidawi; Mariam M Alhammadi; Moiz O Bakhiet; Fatema M Abdulla
Journal:  Neurosciences (Riyadh)       Date:  2022-01       Impact factor: 0.735

5.  Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis.

Authors:  Fawzi Abukhalil; Bijal Mehta; Erin Saito; Sejal Mehta; Aaron McMurtray
Journal:  Autoimmune Dis       Date:  2015-06-14

6.  Characterization of patients with ocular myasthenia gravis - A case series.

Authors:  Arnon Karni; Ali Asmail; Vivian E Drory; Hadar Kolb; Anat Kesler
Journal:  eNeurologicalSci       Date:  2016-04-25

7.  Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.

Authors:  Kee Hong Park; Patrick Waters; Mark Woodhall; Bethan Lang; Thomas Smith; Jung-Joon Sung; Kwang-Kuk Kim; Young-Min Lim; Jee-Eun Kim; Byung-Jo Kim; Jin-Sung Park; Jeong-Geon Lim; Dae-Seong Kim; Ohyun Kwon; Eun Hee Sohn; Jong Seok Bae; Byung-Nam Yoon; Nam-Hee Kim; Suk-Won Ahn; Jeeyoung Oh; Hyung Jun Park; Kyong Jin Shin; Yoon-Ho Hong
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

8.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.